First Drug for Nonrelapsing MS Progression on the Horizon
Current therapies for multiple sclerosis (MS) focus on reducing the frequency and severity of relapses after periods of recovery or remission, leaving patients with nonrelapsing secondary progressive multiple sclerosis (SPMS) without effective options to slow the steady neurodegeneration. But the investigational drug tolebrutinib, a Bruton tyrosine kinase inhibitor, could delay these worsening effects, a phase 3 trial suggests.
Current therapies for multiple sclerosis (MS) focus on reducing the frequency and severity of relapses after periods of recovery or remission, leaving patients with nonrelapsing secondary progressive multiple sclerosis (SPMS) without effective options to slow the steady neurodegeneration. But the investigational drug tolebrutinib, a Bruton tyrosine kinase inhibitor, could delay these worsening effects, a phase 3 trial suggests.
